In use product safety assessment report for infliximab biosimilars

Varinder Rai, Regional Medicines Information Manager, London Medicines Information ServicePublished

The availability of seven infliximab preparations (the intravenous originator, four intravenous biosimilars and two subcutaneous products) in the UK market creates a potential for confusion in the prescribing, dispensing, and administration of these products.  This UKMi Product Safety assessment summarises practical in-use safety considerations associated with the use of infliximab products: Flixabi®, Inflectra®, Remsima® intravenous, Remsima subcutaneous, Zessly®. Potential next steps and mitigation actions are suggested.

UKMi Product Safety assessments are produced using the validated UKMi product assessment tool.

 

 

Attachments